BackElranatamab
Overview + Rationale
- B-cell maturation antigen (BCMA) is a tumor necrosis factor receptor superfamily member that is expressed predominantly on mature B cells
- BCMA mediates survival of antibody-secreting plasma cells after binding to its ligands BAFF (B-cell activating factor of the TNF family) and APRIL (a proliferation inducing ligand)
- In multiple myeloma, BCMA is widely expressed on malignant plasma cells
Mechanism of Action
Elranatamab bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells caused proinflammatory cytokine release and resulted in multiple myeloma cell lysis.
Stage of Development
Elranatamab is being investigated as a single agent and in combination with other agent(s) in the following disease settings.
Phase 1B/2 Combination and Monotherapy
Phase 2 Monotherapy*
Phase 3 Monotherapy
Phase 3 Monotherapy and Combination
This information is current as of February 4th 2025.
*Closed to Enrollment
REFERENCES: ELREXFIO™ (elranatamab-bccm) US Prescribing Information; Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 2012;32:287-305. Tai YT, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/elranatamab; Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187-1199; National Cancer Institute. NCI Drug Dictionary: elranatamab. Accessed May 17, 2023; Panowski et al., Mol Cancer Ther 2019;18:2008-20; ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06215118; https://clinicaltrials.gov/study/NCT05675449; https://clinicaltrials.gov/study/NCT05090566; https://clinicaltrials.gov/study/NCT04649359; https://clinicaltrials.gov/study/NCT05228470; https://clinicaltrials.gov/study/NCT06152575; https://clinicaltrials.gov/study/NCT05014412; https://clinicaltrials.gov/study/NCT05317416; https://clinicaltrials.gov/study/NCT05020236; https://clinicaltrials.gov/study/NCT05623020; https://clinicaltrials.gov/study/NCT05020236 Accessed January 16, 2025.